Work

Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

Year: 2022

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2022-ct184

Authors: Elaine Shum, Yasir Elamin, Karen L. Reckamp, Zofia Piotrowska, Julia Rotow, Daniel S. Tan, Koichi Goto, Jagan Parepally, Faris Albayya, Melinda Louie-Gao, Renata Sawtell, Alena Zalutskaya, David Spigel

Institutions: NYU Langone Health, The University of Texas MD Anderson Cancer Center, Cedars-Sinai Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, National Cancer Centre Singapore, National Cancer Center Hospital East, Blueprint Medicines (United States), Sarah Cannon

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4282960232

Cites:

Cited by: 12

Related to: 10